Guggenheim Reiterates Buy Rating on Monte Rosa Therapeutics, Inc. (GLUE)

Market Context

Monte Rosa Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $24.20 with a market capitalization of $1.1B. The stock has gained 386.9% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Monte Rosa Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Monte Rosa Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 30, 2026	Guggenheim	Buy	N/A
May 11, 2026	JP Morgan	Overweight	N/A
Mar 18, 2026	Wells Fargo	Overweight	N/A
Mar 18, 2026	Guggenheim	Buy	N/A
Jan 14, 2026	Piper Sandler	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View GLUE Stock Page